Reducing late-stage attrition is a key goal in ensuring successful and economically feasible drug development. The ability to select the highest quality candidates for further development requires better pre-clinical models, translational biomarkers and imaging, predictive modeling, earlier POC studies, and an iterative process where clinical information can feed back into basic research to improve decision making. The Translational Medicine meeting will gather decision makers from big pharma, biotech, academia, technology providers and CROs to discuss implementation strategies, models and case studies in bridging the pre-clinical/clinical interface.

Topics to be covered include:

• Strategies to reduce late-stage attrition

• Biomarkers to enable go/no-go decisions

• ROI on enabling technologies

• Model-based drug development

• Evaluating and improving pre-clinical models

• Rational patient selection

• Biomarker translation from animal to FIH studies

• Role of consortia in translational medicine

• Integrating pre-clinical and clinical information

• Iterative learning between clinical and pre-clinical development

• Translational imaging

• Phase 0 and adaptive trial design

Deadline for submission is Friday, August 1, 2008.

Please click here to submit your proposal. 

For more information, please contact:
Julia Boguslavsky, Executive Director, Conferences
E-mail: juliab@healthtech.com  

For sponsorship information, please contact:
Carol Dinerstein, Senior Manager, Business Development
781-972-5471 or dinerstein@healthtech.com 

Jon Stroup, Manager, Business Development
781-972-5483 or jstroup@healthtech.com